Dipak Panigrahy

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc PPARalpha deficiency in inflammatory cells suppresses tumor growth
    Arja Kaipainen
    Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 2:e260. 2007
  2. pmc Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital Boston, Boston, Massachusetts, USA
    J Clin Invest 122:178-91. 2012
  3. pmc EET signaling in cancer
    Dipak Panigrahy
    Vascular Biology Program, Boston Children s Hospital, Division of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer Metastasis Rev 30:525-40. 2011
  4. pmc Cytochrome P450-derived eicosanoids: the neglected pathway in cancer
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital Boston, Boston, MA, USA
    Cancer Metastasis Rev 29:723-35. 2010
  5. pmc PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:985-90. 2008
  6. pmc Epoxyeicosanoids promote organ and tissue regeneration
    Dipak Panigrahy
    Vascular Biology Program and Department of Surgery, Boston Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 110:13528-33. 2013
  7. ncbi request reprint PPARgamma as a therapeutic target for tumor angiogenesis and metastasis
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital, Department of Surgery, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 4:687-93. 2005
  8. ncbi request reprint Therapeutic potential of thiazolidinediones as anticancer agents
    Dipak Panigrahy
    Children s Hospital, Research Building, Floor 12, Boston, MA, USA
    Expert Opin Investig Drugs 12:1925-37. 2003
  9. pmc PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
    Dipak Panigrahy
    Surgical Research Laboratory, Children s Hospital, Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 110:923-32. 2002
  10. pmc Regulation of inflammation in cancer by eicosanoids
    Emily R Greene
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, MA, USA
    Prostaglandins Other Lipid Mediat 96:27-36. 2011

Collaborators

Detail Information

Publications23

  1. pmc PPARalpha deficiency in inflammatory cells suppresses tumor growth
    Arja Kaipainen
    Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 2:e260. 2007
    ..These findings suggest that the absence of PPARalpha activity renders inflammatory infiltrates tumor suppressive and, thus, may provide a target for inhibiting tumor growth by modulating stromal processes, such as angiogenesis...
  2. pmc Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital Boston, Boston, Massachusetts, USA
    J Clin Invest 122:178-91. 2012
    ..Thus, our data indicate a central role for EETs in tumorigenesis, offering a mechanistic link between lipid signaling and cancer and emphasizing the critical importance of considering possible effects of EET-modulating drugs on cancer...
  3. pmc EET signaling in cancer
    Dipak Panigrahy
    Vascular Biology Program, Boston Children s Hospital, Division of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer Metastasis Rev 30:525-40. 2011
    ..In this review, the emerging role of EET signaling in angiogenesis, inflammation, and cancer is discussed...
  4. pmc Cytochrome P450-derived eicosanoids: the neglected pathway in cancer
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital Boston, Boston, MA, USA
    Cancer Metastasis Rev 29:723-35. 2010
    ..In this review, the emerging role in cancer of cytochrome P450 metabolites, notably 20-HETE and EETs, are discussed...
  5. pmc PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:985-90. 2008
    ..Our results provide a mechanistic rationale for evaluating the clinical benefits of PPARalpha agonists in cancer treatment, alone and in combination with other therapies...
  6. pmc Epoxyeicosanoids promote organ and tissue regeneration
    Dipak Panigrahy
    Vascular Biology Program and Department of Surgery, Boston Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 110:13528-33. 2013
    ..Thus, our observations indicate a central role for EETs in organ and tissue regeneration and their contribution to tissue homeostasis. ..
  7. ncbi request reprint PPARgamma as a therapeutic target for tumor angiogenesis and metastasis
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital, Department of Surgery, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 4:687-93. 2005
    ..This will be paramount if the potent biological activity of PPARgamma agonists are to be harnessed for cancer therapy...
  8. ncbi request reprint Therapeutic potential of thiazolidinediones as anticancer agents
    Dipak Panigrahy
    Children s Hospital, Research Building, Floor 12, Boston, MA, USA
    Expert Opin Investig Drugs 12:1925-37. 2003
    ..Further studies suggest that TZDs may be effective in prevention of certain cancers and in the treatment of cancer as adjuvant therapy...
  9. pmc PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
    Dipak Panigrahy
    Surgical Research Laboratory, Children s Hospital, Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 110:923-32. 2002
    ..These results suggest that PPARgamma ligands may be useful in treating angiogenic diseases such as cancer by inhibiting angiogenesis...
  10. pmc Regulation of inflammation in cancer by eicosanoids
    Emily R Greene
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, MA, USA
    Prostaglandins Other Lipid Mediat 96:27-36. 2011
    ..Eicosanoids may represent a missing link between inflammation and cancer and thus could serve as therapeutic target(s) for inhibiting tumor growth...
  11. pmc Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression
    Tadanori Mammoto
    Vascular Biology Program, Department of Surgery, Boston Children s Hospital and Harvard Medical School, Boston, Massachusetts
    Am J Pathol 183:1293-305. 2013
    ..These findings suggest that tumor microenvironment controlled by collagen structure is important in tumor angiogenesis and brain tumor progression...
  12. doi request reprint Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib
    Carmen M Barnes
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA
    Pediatr Res 71:168-78. 2012
    ..We investigated the use of dietary omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) in the treatment of neuroblastoma both as a sole agent and in combination with sunitinib, a broad-spectrum tyrosine kinase receptor inhibitor...
  13. pmc Cytochrome P450 2C8 ω3-long-chain polyunsaturated fatty acid metabolites increase mouse retinal pathologic neovascularization--brief report
    Zhuo Shao
    From the Department of Ophthalmology, Boston Children s Hospital Z S, Z F, J S J, C Hatton, A J, C Hurst, L E, Z C, D P, Y G, D X, K T, H B, J C, L E H S and Department of Pathology, Beth Israel Deaconess Medical Center D P, Harvard Medical School, Boston, MA University Eye Hospital Freiburg, Freiburg, Germany A S Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, NC M L E, F L, D C Z Department of Ophthalmology, Hopital Maisonneuve Rosemont, University of Montreal, Montreal, Quebec, Canada P S and Department of Ophthalmology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden A H
    Arterioscler Thromb Vasc Biol 34:581-6. 2014
    ..The effect of these enzymes and their metabolites on neovascularization is unknown...
  14. doi request reprint The growing role of eicosanoids in tissue regeneration, repair, and wound healing
    Brian T Kalish
    Vascular Biology Program, Boston Children s Hospital, Harvard Medical School, Boston, MA, USA
    Prostaglandins Other Lipid Mediat 104:130-8. 2013
    ..In this review, we describe how this diverse group of molecules is a key regulator of tissue repair and regeneration in multiple organ systems and biologic contexts. ..
  15. pmc Broad spectrum antiangiogenic treatment for ocular neovascular diseases
    Ofra Benny
    Vascular Biology Program and Department of Surgery, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 5:. 2010
    ..Several unique properties make Lodamin especially beneficial for ophthalmic use. Our results support the concept that broad spectrum antiangiogenic drugs are promising agents for AMD treatment and prevention...
  16. pmc The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor
    Cecilia A Fernandez
    Vascular Biology Program, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    J Biol Chem 285:41886-95. 2010
    ....
  17. ncbi request reprint Regulation of soluble neuropilin 1, an endogenous angiogenesis inhibitor, in liver development and regeneration
    Dipak Panigrahy
    1Vascular Biology Program, Boston Children s Hospital 2Department of Surgery, Harvard Medical School 3Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA, United States 4Department of Surgery, Klinikum Grosshadern, LMU Munich, Munich, Germany 5Department of Ophthalmology, Harvard Medical School 6Department of Pathology, Harvard Medical School 7Schepens Eye Research Institute, Massachusetts Eye and Ear, Boston, MA, United States
    Pathology 46:416-23. 2014
    ....
  18. pmc SOCS3 is an endogenous inhibitor of pathologic angiogenesis
    Andreas Stahl
    Department of Ophthalmology, Harvard Medical School, Boston Children s Hospital, Boston, MA 02115, USA
    Blood 120:2925-9. 2012
    ..These results identify SOCS3 as a pivotal endogenous feedback inhibitor of pathologic angiogenesis and a potential therapeutic target acting at the converging crossroads of growth factor- and cytokine-induced vessel growth...
  19. ncbi request reprint Tumor-associated endothelial cells with cytogenetic abnormalities
    Kyoko Hida
    Vascular Biology Program, Department of Surgery, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 64:8249-55. 2004
    ..FISH analysis of tumor sections also showed endothelial cell aneuploidy. We conclude that tumor endothelial cells can acquire cytogenetic abnormalities while in the tumor microenvironment...
  20. pmc Adipose tissue mass can be regulated through the vasculature
    Maria A Rupnick
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:10730-5. 2002
    ..We conclude that adipose tissue mass is sensitive to angiogenesis inhibitors and can be regulated by its vasculature...
  21. ncbi request reprint Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)
    Anette Duensing
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Oncogene 23:3999-4006. 2004
    ....
  22. ncbi request reprint Specific uptake of 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors
    Jason L J Dearling
    Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Boston Children s Hospital, Boston, MA 02115, USA
    Nucl Med Biol 40:788-94. 2013
    ..In an effort to begin to address this limitation, we evaluated the tumor uptake of (99m)Tc-NC100692, a cyclic RGD peptide that binds to αvβ3 with ~1-nM affinity, in an αvβ3-positive tumor model as well as its in vivo specificity...

Research Grants1

  1. Control of cancer and metastasis by endothelial-derived epoxyeicosatrienoic acids
    Dipak Panigrahy; Fiscal Year: 2010
    ..Conversely, blocking the EET pathway may offer a new strategy to block tumor blood vessels and, hence, help combat cancer. Thus, novel drugs which block EETs will be tested in preclinical trials to confirm their activity. ..